Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 7Endocrine 7Thoracic 2Sarcoma 1NET 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Sarcoma 160Glioblastoma 86Gliosarcoma 79Brain Neoplasms 52Central Nervous System Neoplasms 47Osteosarcoma 43Astrocytoma 40Sarcoma, Ewing 39Neoplasm Metastasis 37Melanoma 35Rhabdomyosarcoma 34Neoplasms 34Ovarian Neoplasms 33Glioma 32Neuroblastoma 30Breast Neoplasms 30Oligodendroglioma 29Lymphoma 28Recurrence 27Colorectal Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Dendritic Cell Sarcoma, Interdigitating 22Stomach Neoplasms 21Lymphoma, Non-Hodgkin 21Gastrointestinal Stromal Tumors 20Carcinoma, Renal Cell 19Sarcoma, Synovial 18Pancreatic Neoplasms 18Lymphoma, Follicular 18Neurofibrosarcoma 17

Interventions

tislelizumab 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Carcinoma, Anaplastic × Sarcoma × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡